These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36658402)

  • 1. Incidence and risk factors of SARS-CoV-2 infection among workers in a public health laboratory in Tunisia.
    Kharroubi G; Cherif I; Ghawar W; Dhaouadi N; Yazidi R; Chaabane S; Snoussi MA; Salem S; Ben Hammouda W; Ben Hammouda S; Gharbi A; Bel Haj Hmida N; Rourou S; Dellagi K; Barbouche MR; Benabdessalem C; Ben Ahmed M; Bettaieb J
    Arch Virol; 2023 Jan; 168(2):69. PubMed ID: 36658402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of SARS-CoV-2 antibodies after natural infection: insights from a study on Pasteur Institute of Tunis employees.
    Cherif I; Kharroubi G; Darragi I; El Benna S; Gharbi A; Baccouche A; Souissi C; Bahri O; Ben Ahmed M; Bettaieb J
    Libyan J Med; 2024 Dec; 19(1):2348233. PubMed ID: 38693671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.
    Dhaouadi S; Letaief H; Hechaichi A; Safer M; Moussa R; Bouhali R; Letaief F; Abdelkader L; Ben Salah H; El Mili N; Hammami M; Talmoudi K; Souteyrand Y; Nabeth P; Kouni Chahed M; Bouafif Ép Ben Alaya N
    Epidemiologia (Basel); 2023 Jun; 4(2):188-201. PubMed ID: 37367185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Incidence, signs and symptoms and main risk factors for COVID-19 infection in Health Care Workers: A hospital-wide survey in Salvador, Brazil.
    Montaño-Castellón I; Lins-Kusterer L; Luz E; Pedroso C; Paz M; Brites C
    Braz J Infect Dis; 2022; 26(4):102387. PubMed ID: 35905929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study.
    Pallett SJC; Rayment M; Patel A; Fitzgerald-Smith SAM; Denny SJ; Charani E; Mai AL; Gilmour KC; Hatcher J; Scott C; Randell P; Mughal N; Jones R; Moore LSP; Davies GW
    Lancet Respir Med; 2020 Sep; 8(9):885-894. PubMed ID: 32717210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in Seroprevalence of SARS-CoV-2 Immunoglobulin Antibodies in a Large Midwestern Health Care System.
    Fitzpatrick V; Rivelli A; Blair C; Copeland K; Richards J
    Public Health Rep; 2021 May; 136(3):361-367. PubMed ID: 33673779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2 N and S proteins: mass screening.
    Srivastava AK; Gupta A; Chauhan D; Meena RC; Sugadev R; Eslavath MR; Gupta H; Karuna ; Singh S; Singh Y; Tiwari RP; Kohli V; Varshney R; Ganju L
    Appl Microbiol Biotechnol; 2022 Sep; 106(18):6225-6238. PubMed ID: 35976427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France.
    Decarreaux D; Pouquet M; Souty C; Vilcu AM; Prévot-Monsacre P; Fourié T; Villarroel PMS; Priet S; Blanché H; Sebaoun JM; Deleuze JF; Turbelin C; Werner A; Kochert F; Grosgogeat B; Rabiega P; Laupie J; Abraham N; Guerrisi C; Noël H; Van der Werf S; Carrat F; Hanslik T; Charrel R; De Lamballerie X; Blanchon T; Falchi A
    Viruses; 2022 May; 14(5):. PubMed ID: 35632699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Occupational and Community Risk Factors for SARS-CoV-2 Seropositivity Among Health Care Workers in a Large U.S. Health Care System.
    Baker JM; Nelson KN; Overton E; Lopman BA; Lash TL; Photakis M; Jacob JT; Roback JD; Fridkin SK; Steinberg JP
    Ann Intern Med; 2021 May; 174(5):649-654. PubMed ID: 33513035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study.
    Shields A; Faustini SE; Perez-Toledo M; Jossi S; Aldera E; Allen JD; Al-Taei S; Backhouse C; Bosworth A; Dunbar LA; Ebanks D; Emmanuel B; Garvey M; Gray J; Kidd IM; McGinnell G; McLoughlin DE; Morley G; O'Neill J; Papakonstantinou D; Pickles O; Poxon C; Richter M; Walker EM; Wanigasooriya K; Watanabe Y; Whalley C; Zielinska AE; Crispin M; Wraith DC; Beggs AD; Cunningham AF; Drayson MT; Richter AG
    Thorax; 2020 Dec; 75(12):1089-1094. PubMed ID: 32917840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.